


# Isotachophoresis Improves Nucleic Acid Extraction and Purification from FFPE Samples

Formalin-fixed, paraffin-embedded (FFPE) tissue remains the preferred method of tissue preservation for clinical specimens. Compared to other methods of tissue preservation, FFPE samples are relatively stable at room temperature. This enables FFPE samples to be stored for long periods of time without the need for expensive refrigeration equipment or large amounts of facility space.

For histological or morphological analyses, FFPE samples can be easily sectioned and stained to visualize both morphological and molecular features to identify disease states. Nucleic acids within the preserved tissue can be extracted and purified for downstream applications using PCR, quantitative PCR (qPCR) and next-generation sequencing (NGS). For these reasons and more, clinicians and researchers will likely continue to depend on the analysis of genetic material obtained from FFPE samples for years to come.

## Challenges With Current FFPE Workflows

To use FFPE samples for molecular analysis, researchers are faced with several challenges. Formalin fixation, the process used to generate FFPE samples, is not standardized and can introduce greater variation across samples prepared by different clinicians or at different times. Studies conducted more than 20 years ago found that the condition of the tissue sample, mode of formalin use, and time of fixation can all affect the integrity of nucleic acids, which can compromise downstream analysis<sup>1</sup>. Furthermore, the buffers used during the fixation process can lead to the deamination of cytosine bases and single nucleotide modifications<sup>2</sup>. Fixation also induces cross-linking of nucleic acids with proteins as well as to other nucleic acids. To address cross-linking and deamination, samples must be treated in various ways to remove paraffin and reverse cross-linking while avoiding additional damage prior to nucleic acid extraction. These treatments, while necessary to obtain high-quality nucleic acid for molecular analysis, are time-consuming and do not address any fragmentation that may have occurred.



**FIGURE 1** Overview of traditional workflow of preparing lysate from FFPE samples for purification.

With an increasingly diverse set of genomic tools at their disposal, researchers and clinicians benefit from extracting as much nucleic acid as possible from each FFPE sample while still meeting the quality required for a more sensitive analysis method, such as NGS. While some nucleic acid extraction and purification technologies claim to be optimized for use with FFPE samples, they can further compromise the quality of the nucleic acids extracted and fail to extract all the nucleic acid available. These technologies also employ multi-step workflows that require optimal conditions at each step for successful extraction.

## Challenges With Existing Purification Technologies


In recent years, most researchers have replaced liquid-liquid extraction techniques, such as phenol-chloroform extraction, with technologies that rely on a “catch-and-release” approach based on the principle of solid phase extraction. Two common examples of this approach are column-based and bead-based extractions. Both methods require that the FFPE sample is first chemically de-paraffinized and de-crosslinked, after which the nucleic acid is bound to a solid surface — silica in the case of columns and carboxyl or silica paramagnetic coatings in the case of beads. The solid surface is then washed with a buffer to remove any unbound molecules. Finally, the bound nucleic acid is released from the solid surface into a solution using a solvent. This final step, referred to as an elution, generates an eluate composed of nucleic acid and buffer that can be used as an input for downstream analyses.

The typical workflow used by column- and bead-based purification technologies is tedious and time-intensive. Each methodology requires careful optimization of several steps to achieve the desired yield and quality of the nucleic acid extracted. Before binding the nucleic acid to a solid surface, the sample must be fully deparaffinized, de-crosslinked and lysed. Chaotropic salts are added during lysis to destabilize proteins (including nucleases) and dissociate nucleic acids. This enables nucleic acid to bind to the solid surface. The entire solution is then centrifuged and drawn through a silica column or thoroughly mixed with coated beads.


After the binding step, the columns or beads are thoroughly and repeatedly washed with chaotropic salts and ethanol to remove residual impurities. Typically, a wash cycle consists of the addition of a wash buffer containing a low concentration of chaotropic salt to the column or bead solution, followed by centrifugation or mixing and aspiration, respectively. This is followed by one or more cycles with ethanol used in place of salt to remove residual salt. As with the binding step, the wash step requires optimization as well. Failure to remove residual salt, which can impede the elution of nucleic acids, can lower recovery.

In the final elution step, solvent, or water, is added to the column or bead solution to dissociate the DNA from the solid surface. Prior to the addition of a solvent, the beads or column must be free of ethanol. Ethanol contamination in columns is avoided by dry centrifugation. Failure to remove the ethanol can inhibit downstream assays. Over-drying at this stage can damage the beads and reduce the amount of nucleic acid recovered.

### Column-based Kit Workflow



### Bead-based Kit Workflow




**FIGURE 2** Examples of the typical workflows for column- and bead-based extraction technologies.

## Isotachophoresis Offers A Better Approach

Solid phase extraction technologies frequently used to purify nucleic acids from FFPE can add to the inherent sample variability and produce eluates that are not of high enough quality and/or yield for downstream applications. Though some newer NGS technologies can cope with lower concentrations to overcome suboptimal purification conditions, the samples purified by column- or bead-based methods may still have different impacts on downstream sequencing due to damage or bias that occurs to nucleic acids during purification<sup>4</sup>. This can contribute to non-uniform coverage of sequencing targets and lowered NGS efficiency. In addition, the entire workflow is laborious and can take anywhere from several hours to an entire working day to complete. Attempts to address this with automation have shown in recent studies to yield lower concentrations of nucleic acids when compared to manual methods for extraction from FFPE samples<sup>5-7</sup>.

Isotachophoresis separates and concentrates charged molecules in solution, solely based on their electrophoretic mobility or the speed at which the molecules move within the applied electric field<sup>11</sup>. As such, isotachophoresis offers a compelling approach for separating negatively charged nucleic acids from impurities that are positively charged, non-charged, or that are negatively charged with lower electrophoretic mobility.

### Simple, Automated Charge-based Sample Prep in Solution




**FIGURE 3** Conceptual representation of isotachopheresis in the following steps: 1) Lysate containing nucleic acids is loaded into the microfluidic channel between a leading electrolyte containing ions with a faster electrophoretic mobility than nucleic acids and a trailing electrolyte containing ions with a slightly slower electrophoretic mobility. 2) Electrical current is applied to the channel, causing nucleic acids to move through the solution toward the positive electrode. As this happens, the leading and trailing ions form a sharp electric field gradient, and nucleic acids focus toward the gradient. This is the ITP zone. Impurities are not collected into the zone because their mobilities are not bracketed by the leading and trailing ions. 3) The band moves into an extraction well. The field gradient is detected by a sensor, and the system shuts down the electric current. The result is purified nucleic acid in a well accessible by a pipette tip.

Throughout this process, nucleic acids are never bound to a solid phase, exposed to wash reagents or stripped from a solid phase for collection. As such, the risk of introducing contaminants from the solid phase or chemicals is avoided. Since nucleic acids do not have to be physically bound and stripped from a solid phase, there is no risk of unbound material washing away or bound material failing to elute. The result is a higher yield of pure nucleic acid that is less fragmented, more representative of the native nucleic acids in the sample and free from bead or wash buffer contamination.

## Ionic System Offers a Superior Workflow for Purification from FFPE Samples

The Ionic® Purification System automates purification of nucleic acids from FFPE samples using isotachopheresis. The workflow to prepare and process samples using the system requires significantly fewer steps and less hands-on time compared to workflows using columns or beads. At a high level, the workflow can be broken down into two steps:



**FIGURE 4** Typical workflow for the purification of FFPE samples using the Purigen Ionic Purification System.

### STEP 1

Add lysis buffer to an FFPE section or scroll and apply heat to prepare a lysate. This requires approximately 5 minutes of hands-on time and a total of 2 hours and 15 minutes for each batch of eight samples.

### STEP 2

Add the lysate and run buffers to the Ionic® Fluidic Chip and start a purification run. This requires approximately 10 minutes of hands-on time and a total of 1 hour of hands-off time on the Ionic system to process all eight samples.

A key difference between isotachopheresis and traditional methods for nucleic acid purification is de-paraffinization. Paraffin is removed as an impurity during isotachopheresis because its constituent hydrocarbons have almost no electrophoretic mobility, whereas nucleic acids have a high electrophoretic mobility. This eliminates the need to physically scrape away paraffin from samples or use harsh chemicals such as xylene to remove paraffin. Similarly, the workflow does not require that samples be exposed to chaotropic salts, ethanol or other reagents used in binding nucleic acid to, or removing it from, a solid surface.

The simplified process relies only on the free-solution electrophoretic mobility of nucleic acids, a property that is not sensitive to fragment length or sequence, to deliver an unbiased reflection of the nucleic acids present in an FFPE sample. Nucleic acid is processed on the chip and deposited into a well for immediate retrieval. The final extract is in a buffer that is immediately compatible with downstream applications including PCR, qPCR and library preparation for NGS.

# Improved Purification of FFPE Samples for Amplification-based Analyses


## OVERVIEW

Among the advantages of using the Ionic system to purify DNA from FFPE samples are an increased amplifiable yield and improved coverage uniformity in amplicon-based NGS workflows. Amplicon-based sequencing allows researchers to detect variation in genomic regions of interest in complex samples such as tumors. The sequencing process requires NGS libraries with a specific range of fragment lengths. The range of supported fragment lengths can vary by kit, but typically falls between 100 and 1,000 base pairs. Since nucleic acids within an FFPE block can be denatured and fragmented during the fixation process itself, it is critical to prevent fragmentation in the purification process. It is also important to purify fragments within the target range without any bias to fragments of a specific length or sequence. Underrepresentation of certain fragment lengths or types for any reason can require higher levels of sequencing coverage, resulting in higher sequencing costs

## ASSESSMENT OF AMPLIFIABLE YIELD

There are three commonly used techniques to determine the yield of nucleic acids produced from the purification of an FFPE sample: UV absorbance, fluorescence and qPCR. While UV absorbance is widely used because of its comparatively lower cost and simple workflow, it is less sensitive and can be biased by the presence of single-stranded DNA, RNA and free nucleotides. The use of fluorescence requires labeling with a fluorescent dye, which can be less successful when nucleic acids are fragmented. In comparison to the previously mentioned techniques, qPCR is more sensitive and can detect trace amounts of nucleic acids<sup>8-9</sup>. qPCR also detects inhibitors present in the sample and can be used to estimate the level of fragmentation present<sup>10</sup>.

In the following example, a comparison of qPCR results based on replicate DNA samples from 32 FFPE blocks show that the amplifiable yield is greater for most samples when purified using the Ionic system. Amplification of an 80 base-pair amplicon was measured (QIAGEN MRef multicopy reference assay), showing that the amplifiable yield obtained from the Ionic system exceeded the yield from samples prepared using a commercial column-based extraction kit for 31 of 32 blocks. For these comparisons, the quantity of DNA recovered using the Ionic system averaged 3.5 times the amount of the DNA recovered using a column-based kit.




**FIGURE 5** Comparison of DNA yields from consecutive sections of 18 FFPE tissue blocks purified on the Ionic Purification System using the G2 FFPE DNA kit or a commercially available column-based kit. The total DNA yield for each sample was determined by multiplying the extract volume by the DNA concentration derived from the Qubit 1x dsDNA High Sensitivity assay. Error bars represent standard deviation from the average DNA yield. More DNA is recovered using the G2 FFPE DNA kit for each of the 18 FFPE blocks with expected increase in DNA yield of 3-5x on average compared to the column-based kit, with greater yield advantages for lower yielding samples.

DQC Value	DNA Quality
> 5	Excellent DNA quality
1.1 – 5.0	Good DNA quality
0.1 – 1.0	Acceptable DNA quality
< 0.1	Poor DNA quality

**TABLE 1** Correlation between DQC score and DNA quality for Agilent QC Plex assay.

To determine the suitability of DNA from an FFPE sample for amplicon-based sequencing, a qPCR assay with multiple primer sets that yield a range of amplicon sizes (such as the QC Plex assay from Agilent Technologies) is used. The success of amplifying longer fragments as opposed to shorter fragments is assessed with a fragment analyzer, such as the Agilent Technologies TapeStation. This approach produces a quality score (DQC value) that is used to QC extracts from sample purification experiments prior to preparing NGS libraries. A higher quality score correlates to a higher relative abundance of the longer amplicons, indicating that the sample is suitable for amplicon-based sequencing. The table to the right describes the correlation between DQC score and DNA quality for the Agilent QC Plex assay.

A comparison of QC Plex assay scores (DQC score) from the samples described above indicates that higher-quality nucleic acid was obtained from 27 of the 32 FFPE samples when using the Ionic system. Furthermore, the score of "No Amp" reported for 14 of the samples purified using columns indicates that no DNA amplification was observed. By comparison, all samples purified by the Ionic system resulted in observable amplification levels.




**FIGURE 6** Comparison of DNA from consecutive sections of 18 FFPE tissue blocks purified on the Ionic Purification System using the G2 FFPE DNA kit or a commercially available column-based kit. The DNA Integrity Number (DIN) was calculated for each extract using a Genomic DNA ScreenTape on the Agilent TapeStation. The Ionic G2 DNA quality is typically higher than the column-based competitor, and nearly half of the column-based eluates had a concentration that was below that required for DIN score calculation.


## Improved Coverage Uniformity for Amplicon-Based Sequencing of FFPE Samples

Amplicon-based sequencing requires regions of interest within a sample to be enriched through targeted amplification prior to sequencing. This is accomplished by performing PCR with sequence-specific oligonucleotide primers prior to sequencing. Samples purified with a technique that provides less uniform recovery — and therefore less coverage uniformity — may require additional cycles of sequencing to build enough coverage across the sample to confidently call variants. This “over-sequencing” to accommodate non-uniform sample coverage can increase overall sequencing costs.


A comparison of sequencing results from three FFPE blocks (BM, CP and LO), where the QC Plex assay scores for samples purified by the Ionic system and by a column-based kit were both “Acceptable,” demonstrates more uniform coverage for samples purified by the Ionic system. To demonstrate this, a sequencing library was prepared from each sample using the Agilent SureMASTR amplicon-based sequencing method. Results from each sample were then compared to a coverage profile generated from a high-quality reference sample, Coriell Institute NA12878 DNA (GM12878 cell line). A coverage ratio equal to 1 indicates that the DNA quality recovered from the FFPE sample is equivalent to the reference sample. The resulting ratio of reference coverage to sample coverage for each purification method clearly shows that libraries generated using DNA purified by columns have less uniform coverage than the reference when compared to libraries generated using the DNA from consecutive slices purified using the Ionic system. These libraries would require 20x to 50x greater sequencing depth to achieve equal sequencing coverage of the least-covered targets compared to the libraries prepared from samples purified using the Ionic system.



**FIGURE 7** Libraries were prepared and enriched for the SureMASTR Tumor Hotspot Panel (Agilent) and sequenced on the Illumina MiSeq sequencer. Coverage was assessed against control libraries constructed from a high-quality reference sample, Coriell Institute NA12878 DNA (GM12878 cell line). Coverage was compared to the reference as a fraction of total hits. The log ratio of the coverage fraction by target is plotted.



**FIGURE 8** Data from the sequencing of the SureMASTR Tumor Hotspot libraries is plotted here as a coverage ratio versus the amplicon size. The higher intensity of color at each data point indicates overlapping data points. The underrepresented targets in the libraries made from column-purified DNA occur most often in the longer targets.



**FIGURE 9** Sequencing libraries were prepared from DNA extracted using either the Ionic system or a column-based kit. Each set contained samples composed of 1, 2, or 4 FFPE tissue sections of 5  $\mu$ m thickness. Each set also contained replicate 2-section and 4-section samples. Libraries were prepared using the SureMASTR Tumor Hotspot Panel (Agilent) and sequenced on the Illumina MiSeq sequencer. Library coverage was normalized to the lowest number of reads after sequencing. Coverage was assessed against control libraries constructed from a high-quality reference sample, Coriell Institute NA12878 DNA (GM12878 cell line). Coverage was compared to the reference as a fraction of total hits. The log ratio of the coverage fraction by target is plotted. After sequencing, 26 variants were detected in samples prepared by both the Ionic system and using a column-based kit. 100% of the 26 expected variants were detected in 4 out of 5 samples purified on the Ionic system with no difference between replicates.

By replotting the data in the graph above, a correlation between coverage ratio and amplicon length can be shown. The graphs below illustrate this correlation and show that as amplicon length increases, the coverage from samples purified by a column-based approach is lower than the reference. A similar correlation is not observed in the data from the samples purified by the Ionic system. This indicates that the column-based extraction technology may inherently bind and release amplicons of a certain length better than others. The amount of bias shown here for column-based extraction is significant, with some targets represented at only 1% of the expected fraction of the population. This could severely limit the ability to call variants on low-coverage targets and would require substantially greater sequencing depth to confidently identify clinically relevant variants.

To further illustrate the impact of coverage uniformity on variant calling, **Figure 9** depicts a comparison of sequencing results from replicate sections from the same FFPE block (CT) purified using both the Ionic system and a column-based kit. Each cluster of points in the upper section of the figure represents the log ratio of the target coverage obtained from each sample in comparison to the coverage of a high quality reference sample. In the lower section of the figure, the bars below each cluster indicate the portion of variants that were commonly detected in all sample types identified after sequencing. 100% of the 26 variants expected were detected in four out of five samples purified on the Ionic system. 100% of the variants were detected in both replicates of the 2-section and 4-section samples purified on the Ionic system. By comparison, only two out of the five samples purified using a column-based kit provided a similar result. Furthermore, fewer variants were identified in both the 2-section and 4-section replicates. The coverage from the two samples where 100% of the variants were detected is also more uniform by comparison to the other samples also purified using a column-based kit. This implies that less uniform coverage from an under-representation of certain targeted amplicons can potentially result in variability across replicate sections and failure to detect variants. This effect is demonstrated here at 100% allele frequency. The effect would be even more pronounced at a lower frequency, which can be the case for real tumor tissue samples.



## Summary

The creation of FFPE samples will remain a go-to method to preserve and archive tissue samples for molecular analyses. While samples are subject to variability from preparation techniques, they are stable at room temperature, can be stained for histological purposes, and preserve nucleic acids and proteins for downstream molecular analyses that may occur several years after they have been made.

Since the process of creating FFPE samples introduces the risk of nucleic acid degradation, purification technologies that offer maximum recovery of nucleic acids without adding damage or bias offer significant advantages over the current technologies available. With a simplified workflow and separation based solely on the electrophoretic mobility of the molecules in a sample, Purigen's Ionic Purification System offers an alternative for FFPE sample purification for NGS that has less risk of further damage to nucleic acids or bias toward specific fragment length or GC content.



## References

- 1 *Am J Pathol.* 2002 Dec;161(6):1961-71. Doi: [https://doi.org/10.1016/S0002-9440\(10\)64472-0](https://doi.org/10.1016/S0002-9440(10)64472-0)
- 2 *PLoS One.* 2019 Apr 11;14(4). Doi: <https://doi.org/10.1371/journal.pone.0211400>
- 3 *PLoS One.* 2017 May 5;12(5). Doi: <https://doi.org/10.1371/Journal.pone.0176848>
- 4 *PLoS One.* 2018 May 17; 13(5). Doi: <https://doi.org/10.1371/journal.pone.0197456>
- 5 *World J Clin Oncol.* 2019 Sep 24;10(9):307-317. Doi: <https://doi.org/10.5306/Wjco.v10.I9.307>
- 6 *Clin Lab Anal.* 2007 July 9;21(4):244-8. Doi: <https://org/10.1002/jcla.20174>
- 7 *J Lab Autom.* 2015. Dec;20(6):642-51. Doi: <https://doi.org/10.1177/2211068214565903>
- 8 *PLoS One.* 2016 Mar 3;11(3). Doi: <https://doi.org/10.1371/Journal.pone.0150528>
- 9 *Int J Oncol.* 2016 Oct;49(4):1755-65. Doi: <https://doi.org/10.3892/Ijo.2016.3654>
- 10 *Biotechniques.* 2009 Nov;47(5):941-9. Doi: <https://doi.org/10.2144/000113244>
- 11 *J Chromatogr A.* 2014 Mar 28;1335:105-20. Doi: <https://doi.org/10.1016/j.chroma.2013.12.027>

**Contact your Bionano Regional Business Manager to get started.**



To order, please contact [orders@bionano.com](mailto:orders@bionano.com) or



Call **1.858.888.7600** or contact your sales person directly.

For Research Use Only. Not for use in diagnostic procedures.

Bionano™ and Ionic® are trademarks of Bionano Genomics, Inc.

LIT-00004\_Rev A\_Ionic Macrodissection App Note\_Effective Date 04/21/2023

**bionano**®